US-China biotech deal wave expected as Washington eases curbs

Analysts expect a surge in US-China biotech out-licensing deals as Washington reportedly leans away from sweeping restrictions, a reversal from prior tightening. The US Treasury is drafting investment rules, and Beijing's five-year plan supports the sector. This signals a thaw in bilateral tech trade, though final rules remain uncertain.